Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

21 Mar 2018

• By Emily Hayes

The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.

Monomethyl auristatin E (MMAE, vedotin), the cytotoxic payload of brentuximab vedotin antibody-drug conjugate. Atoms are represented as spheres with conventional color coding: hydrogen (white), etc — Seattle Genetics' antibody drug conjugate Adcetris combines an antibody and cytotoxic payload of monomethyl auristatin E (depicted above) targeted at CD30 on lymphoma cells.

Seattle Genetics Inc. sees its antibody drug conjugate Adcetris (brentuximab vedotin) as setting a new standard of care in the frontline treatment of classical Hodgkin lymphoma following US FDA approval for use with chemotherapy in previously untreated Stage III and Stage IV disease on March 20.

Adcetris, which is partnered ex-US with Takeda Pharmaceutical Co. Ltd.,combines an antibody with the cytotoxic payload of the microtubule-disrupting agent monomethyl auristatin E (MMAE) targeted at CD30 on lymphoma cells

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

12 May 2025

• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.